Monoclonal antibody therapy in multiple myeloma, Leukemia, vol.31, pp.1039-1086, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01795709
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study ,
Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nat Rev Cancer, vol.8, pp.121-153, 2008. ,
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, vol.19, pp.202-210, 2013. ,
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.374, pp.311-333, 2016. ,
Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma, J Clin Oncol J Am Soc Clin Oncol, vol.35, pp.826-859, 2017. ,
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-203, 2002. ,
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.19, pp.1248-52, 2005. ,
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1, Blood, vol.128, pp.1834-1878, 2016. ,
Apoptotic machinery diversity in multiple myeloma molecular subtypes, Front Immunol, vol.4, p.467, 2013. ,
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma, Br J Cancer, vol.103, pp.1808-1822, 2010. ,
ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, pp.3901-3911, 2011. ,
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.30, pp.761-765, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01411102
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, pp.1329-1368, 2011. ,
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein, Leukemia, vol.17, pp.211-220, 2003. ,
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients, J Clin Oncol J Am Soc Clin Oncol, vol.23, pp.4089-99, 2005. ,
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma, Leuk Lymphoma, vol.50, pp.559-65, 2009. ,
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia, Br J Haematol, vol.164, pp.352-65, 2014. ,
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015070) in multiple myeloma, Blood, vol.109, pp.5430-5438, 2007. ,
An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.435, pp.677-81, 2005. ,
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J Clin Oncol J Am Soc Clin Oncol, vol.30, pp.488-96, 2012. ,
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia, N Engl J Med, vol.378, pp.1107-1127, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01815999
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, pp.8750-8759, 2015. ,
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study, Lancet Oncol, vol.19, pp.216-244, 2018. ,
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol, vol.93, pp.401-408, 2018. ,
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia, Cancer Discov, vol.6, pp.1106-1123, 2016. ,
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.28, pp.210-212, 2014. ,
Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models, Mol Cancer Ther, vol.15, pp.1132-1176, 2016. ,
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax, Leukemia, vol.30, pp.1086-93, 2016. ,
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax, Oncogene, vol.35, pp.3955-64, 2016. ,
Efficacy of venetoclax as targeted therapy for relapsed/ refractory t(11;14) multiple myeloma ,
URL : https://hal.archives-ouvertes.fr/inserm-01631468
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14), Haematologica, vol.102, pp.112-116, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01445538
Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory multiple myeloma, Blood, vol.130, p.3131, 2017. ,
Promising efficacy and acceptable safety of C ,
, venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM, Blood, 2017.
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism, Blood, vol.127, pp.3215-3239, 2016. ,
BH3 profiling in whole cells by fluorimeter or FACS, Methods San Diego Calif, vol.61, pp.156-64, 2013. ,
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, vol.10, pp.389-99, 2006. ,
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer Cell, vol.10, pp.375-88, 2006. ,
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199), Blood Cancer J, vol.5, p.368, 2015. ,
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma, Cancer Res, vol.67, pp.5418-5442, 2007. ,
Flavopiridol enhances ABT-199 sensitivity in unfavourablerisk multiple myeloma cells in vitro and in vivo, Br J Cancer, vol.118, pp.388-97, 2018. ,
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01353369
Potential mechanisms of resistance to venetoclax and strategies to circumvent it, BMC Cancer, vol.17, p.399, 2017. ,
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma, Blood, vol.129, pp.1969-79, 2017. ,
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, pp.4111-4120, 2014. ,
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia, Nat Commun, vol.9, p.727, 2018. ,
Pomalidomide plus low-dose dexamethasone versus highdose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, Lancet Oncol, vol.14, pp.1055-66, 2013. ,
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study, Lancet Oncol, vol.17, pp.27-38, 2016. ,
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, pp.30578-30586 ,
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, vol.27, pp.780-91, 2013. ,
Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective Phase II Study of the Intergroupe Francophone du Myélome, J Clin Oncol J Am Soc Clin Oncol, vol.34, pp.2125-2157, 2016. ,
Combination therapy incorporating Bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14), Eur J Haematol, vol.100, pp.215-222, 2018. ,
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, pp.477-82, 2016. ,
A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers, Cancer Res, vol.77, p.13, 2017. ,
The discovery and preclinical characterization of AMG 176: a first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma, Cancer Res, vol.77, p.13, 2017. ,